DRIO.NASDAQDariohealth CORP
10-Q: DarioHealth Q3 2025: Revenue Declines Amid Strategic Review
Sentiment:
Quarterly Report
DarioHealth Corp. reported a 32.5% revenue decrease in Q3 2025, alongside a reduced net loss and an ongoing strategic review to maximize shareholder value.
Delay expectedTimeline extensions in certain projects due to tariff-related pressures, impacting hardware sourcing and partner-side execution.Prolonged decision-making cycles and implementation delays for several potential partners due to changes in trade policy.
Capital raiseA private placement in September 2025 raised approximately $17,500 thousand in gross proceeds through the sale of 1,154,420 shares of Common Stock and pre-funded warrants to purchase up to 1,558,760 shares of Common Stock.The company refinanced its existing $30,000 thousand credit facility with a new $32,500 thousand credit agreement (Callodine Loan Facility) on April 30, 2025, with an option to draw an additional $17,500 thousand (subject to conditions).Management states that the company intends to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities or a combination of the foregoing, indicating a potential need for further capital raises.
Worse than expectedTotal revenues decreased by 32.5% in Q3 2025 and 11.9% for the nine months ended September 30, 2025, primarily due to the non-renewal of a significant customer.Net loss attributable to common shareholders increased substantially by 29.1% in Q3 2025 and 79.3% for the nine months ended September 30, 2025, indicating a worsening bottom line for common shareholders despite overall net loss reduction.Financial expenses, net, increased significantly, primarily due to the revaluation of pre-funded warrants, contributing to the overall financial burden.
Summary
- Total revenues for Q3 2025 decreased by 32.5% to $5,007 thousand from $7,423 thousand in Q3 2024.
- Total revenues for the nine months ended September 30, 2025, decreased by 11.9% to $17,128 thousand from $19,436 thousand in the same period of 2024.
- Net loss for Q3 2025 decreased by 15.1% to $10,466 thousand from $12,330 thousand in Q3 2024.
- Net loss for the nine months ended September 30, 2025, decreased by 1.3% to $32,683 thousand from $33,115 thousand in the same period of 2024.
- Gross profit margin improved to 60.2% in Q3 2025 (from 52.2% in Q3 2024) and to 57.6% for the nine months ended September 30, 2025 (from 46.6% in 9M 2024).
- Operating expenses decreased significantly, with R&D down 38.9% in Q3 and 41.0% in 9M, and Sales & Marketing down 31.6% in Q3 and 24.4% in 9M.
- The company added 45 new accounts year-to-date in 2025, exceeding its annual goal of 40.
- A 20-for-1 reverse stock split was effected on August 28, 2025, leading to regained Nasdaq compliance by September 12, 2025.
- A private placement in September 2025 raised approximately $17,500 thousand in gross proceeds.
- The Board of Directors initiated a comprehensive strategic review on September 25, 2025, to maximize shareholder value, considering options like a sale, merger, or strategic business combination.
Sentiment
Score: 4
Explanation: While the company showed improved operational efficiency and reduced overall net loss, the significant revenue decline and substantial increase in net loss attributable to common shareholders, coupled with the ongoing strategic review and past debt covenant breach, indicate considerable challenges and uncertainty. The positive aspects are overshadowed by the revenue contraction and the need for a strategic review, suggesting a cautious outlook.
Positives
- Gross profit margin improved significantly, reaching 60.2% in Q3 2025 compared to 52.2% in Q3 2024, and 57.6% for the nine months ended September 30, 2025, compared to 46.6% in the prior year.
- Operating expenses decreased substantially due to efficiency and post-merger integration activities, leading to a reduced operating loss.
- Net loss decreased by 15.1% in Q3 2025 and 1.3% for the nine months ended September 30, 2025, indicating improved cost management.
- The company exceeded its annual goal for new accounts, adding 45 new accounts year-to-date in 2025, including 10 new self-insured employer contracts in Q3 representing 107,000 covered lives.
- Regained compliance with Nasdaq's minimum bid price rule following the reverse stock split.
- Cash and cash equivalents increased to $31,907 thousand as of September 30, 2025, from $27,764 thousand on December 31, 2024.
- Net cash used in operating activities decreased by 37% to $20,054 thousand for the nine months ended September 30, 2025, compared to $31,830 thousand in the prior year.
- Successful equity cure and amendment of the Credit Agreement with Callodine, resetting financial covenants and waiving past breaches.
- Initiated a strategic collaboration with OneStep to enhance fall risk prevention and mobility insights, expanding the multi-condition digital health platform.
Negatives
- Total revenues decreased by 32.5% in Q3 2025 and 11.9% for the nine months ended September 30, 2025, primarily due to the non-renewal of one customer acquired through the Twill acquisition.
- Net loss attributable to common shareholders increased significantly by 29.1% in Q3 2025 to $18,855 thousand and by 79.3% for the nine months ended September 30, 2025, to $51,483 thousand.
- The company continues to incur recurring losses and negative cash flows since inception, with an accumulated deficit of $441,826 thousand as of September 30, 2025.
- Experienced a breach of a financial covenant under the Credit Agreement on August 15, 2025, which, although waived, indicates financial strain.
- Financial expenses, net, increased substantially to $982 thousand in Q3 2025 (from $313 thousand in Q3 2024) and to $4,568 thousand for the nine months ended September 30, 2025 (from financial income of $10,954 thousand in 9M 2024), mainly due to revaluation of pre-funded warrants.
- The market price of common stock has been extremely volatile, ranging from $6.17 to $30.60 per share between January 1, 2025, and November 13, 2025, with equity sales being dilutive to existing stockholders.
Risks
- Inability to satisfy capital needs through financing transactions or otherwise, and dependence on raising additional funds to fund operations until profitability is achieved.
- Inability to meet the requirements of the existing debt facility, as evidenced by the recent covenant breach.
- Challenges in product launches and market penetration plans.
- Inability to maintain relationships with key partners.
- Difficulty in completing required clinical trials and obtaining clearance or approval from the FDA or other regulatory agencies.
- Inability to maintain or protect the validity of U.S. and other patents and intellectual property.
- Inability to retain key executive members.
- Inability to internally develop new inventions and intellectual property.
- Operations in Israel expose the company to political, economic, and military instability, including the multi-front war Israel is currently facing, which could adversely affect operations and financial condition.
- Significant changes or developments in U.S. laws or policies, including trade policies and tariffs, could materially adversely affect the business and financial statements.
- Timeline extensions in certain projects due to tariff-related pressures, impacting hardware sourcing and partner-side execution, leading to prolonged decision-making and implementation delays.
- The market price of common stock has been extremely volatile due to numerous factors beyond control, including short squeezes, analyst comments, large stockholder exits, and general market conditions.
- Continued low stock price could imply a negative valuation of intangible assets and goodwill, potentially resulting in impairment.
Future Outlook
Management believes the company has sufficient funds to support operations for at least twelve months from the issuance date of the interim financial statements. The company expects to incur future net losses and its transition to profitability is dependent on successful product development and commercialization, and achieving adequate revenues. Future operations will be funded through cash on hand, and potential additional private and/or public offerings of debt or equity securities. The Board has initiated a comprehensive strategic review to maximize shareholder value, considering a potential sale, merger, strategic business combination, or continued execution of its current strategy.
Management Comments
- "We are a leading global digital health company with a mission to power the behavior changes that drive better health."
- "We believe that most existing digital health solutions in the market fail to deliver improved health outcomes because users are not engaged due to a lack relevance, personalization, consumerization, and longitudinal data and information."
- "Our D2C marketplace roots and continued focus delivers better user experiences, longer sustained engagement, stronger clinical outcomes, at the most affordable prices, that then delivers the highest return on investment (ROI) in the industry."
- "Our leadership is focused on five chronic conditions diabetes, hypertension, weight management, musculoskeletal, and behavioral health within a single, unified platform."
- "Over 70% of our commercial pipeline and 80% of our new contracts are for multi-condition programs, reflecting growing demand for integrated, value-based digital health solutions."
- "Management believes that the Company has sufficient funds to support its operation for at least a period of twelve months from the date of the issuance of these interim condensed consolidated financial statements."
Industry Context
DarioHealth operates in the rapidly evolving digital therapeutics (DTx) market, which is increasingly focused on integrated, whole-person health solutions. The company's emphasis on engagement, data-driven AI, and personalized care aligns with industry trends seeking to improve health outcomes and reduce costs. The growing demand for multi-condition programs, as evidenced by DarioHealth's commercial pipeline, reflects a broader shift among employers and health plans towards comprehensive digital health platforms. The strategic review indicates a potential consolidation trend or a move to enhance competitive positioning in a fragmented yet growing market.
Comparison to Industry Standards
- The company's focus on a "whole-person health platform" addressing multiple chronic conditions (diabetes, hypertension, weight management, musculoskeletal, behavioral health) is consistent with a growing trend in the digital health industry to offer integrated solutions rather than siloed point solutions.
- The reported gross profit margin improvement (60.2% in Q3 2025 vs 52.2% in Q3 2024) suggests improved operational efficiency or pricing power, which could be a positive differentiator in the competitive digital health space, especially if competitors face similar revenue pressures.
- The significant reduction in operating expenses, particularly R&D and Sales & Marketing, indicates a strong focus on cost control and post-merger integration efficiencies, which is crucial for digital health companies striving for profitability in a market often characterized by high burn rates.
- The company's claim of delivering "the health industry's highest levels of user activation and sustained engagement" and "highest return on investment (ROI) in the industry" (exceeding 5:1 for employers) positions it favorably against competitors, though specific external benchmarks or comparable company data are not provided in the filing to independently verify these claims.
- The strategic collaboration with OneStep for fall risk prevention and mobility analysis demonstrates an expansion into adjacent, high-demand areas within digital health, aligning with the broader industry push for comprehensive and preventive care.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer, Treasurer and Secretary | N/A | Chen Franco-Yehuda | 2025-05-15 | Appointment by the Board of Directors. |
| Non-Executive Director | N/A | Member of a consulting firm | 2025-02-25 | Appointment to the Board. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Reverse Stock Split | Effected a 20-for-1 reverse stock split of outstanding Common Stock, approved by stockholders and board of directors. | 2025-08-28 | Aimed to increase share price to regain Nasdaq compliance, which was achieved. Reduced the number of outstanding shares. |
| Credit Agreement Amendment | Amended the Credit Agreement with Callodine Commercial Finance, LLC to reset financial covenants, replace minimum cash covenant with a $10,000 thousand minimum consolidated unencumbered liquid assets covenant, add monthly 13-week cash-flow reporting, clarify Tranche B as uncommitted, and increase the exit fee by $150 thousand. | 2025-11-05 | Addressed a prior covenant breach, provided more flexible liquidity requirements, but introduced additional reporting obligations and increased potential exit costs. |
| Warrant Repricing | Repriced warrants to purchase 105,707 shares of Common Stock issued to lenders from an exercise price of $16.56 to $15.35 per share. Also amended conversion right of $2,500 thousand loan amount to a conversion price of $15.35 per share. | 2025-11-05 | Potentially makes warrants more attractive to exercise, but could lead to increased dilution for existing shareholders at a lower price. |
| Preferred Stock Certificate of Designation Amendments | Amended and Restated Certificates of Designation for Series A-1, B-1, C, C-1, C-2, D, D-1, D-2, and D-3 Preferred Stock to accelerate mandatory conversion periods into common stock or pre-funded warrants, and to provide holders with options to receive pre-funded warrants in lieu of common stock. | 2025-05-20, 2025-09-18, 2025-09-25 | Resulted in the conversion of all outstanding preferred stock into common stock or pre-funded warrants by September 30, 2025, simplifying the capital structure but potentially increasing common stock outstanding and future dilution. |
| Lock-Up Agreement Amendments | Entered into a Second Amended and Restated Lock-Up Agreement, accelerating the issuance of all share consideration upon a Fundamental Transaction (merger, sale of assets, reclassification of common stock). | 2025-10-20 | Provides an incentive for holders to support a Fundamental Transaction by accelerating their share consideration, potentially facilitating strategic M&A activities. |
| Equity Incentive Plan Amendment | Amended and restated the 2020 Equity Incentive Plan to increase shares available by 6% of outstanding common stock annually from 2026-2030 and authorize restricted stock units. | 2025-07-23 | Increases the pool of shares available for equity compensation, which can be used to attract and retain talent, but also represents potential future dilution for shareholders. |
Related Party Transactions
- On February 25, 2025, a new non-executive director was appointed who is a member of a consulting firm that has provided investment and business consulting services to the company since 2021.
- The company pays the consulting firm a fixed monthly cash retainer of $10 thousand and has issued approximately 12,900 shares of Common Stock and warrants to purchase up to 5,000 shares of Common Stock to the firm.
- Share-based compensation expenses related to this service provider amounted to $35 thousand for Q3 2025 and $135 thousand for 9M 2025.
Stakeholder Impact
- Shareholders experienced significant dilution from recent equity raises and preferred stock conversions. The reverse stock split aimed to maintain Nasdaq listing but doesn't change underlying value. The strategic review could lead to a significant event (sale, merger) impacting share value. Increased net loss attributable to common shareholders is a negative.
- Employees: Post-merger integration activities led to decreased payroll expenses, suggesting potential headcount reductions. Equity incentive plans are in place to attract and retain talent.
- Customers: The non-renewal of a key customer negatively impacted revenue. New client additions, especially for multi-condition programs, indicate continued market acceptance and expansion of covered lives.
- Creditors (Callodine Commercial Finance, LLC): The company breached a financial covenant but secured a waiver and an amendment to the credit agreement, indicating ongoing dialogue and adjustments to debt terms. Warrants issued to lenders and repriced.
- Suppliers: Tariff-related pressures and trade policy changes have caused timeline extensions and delays in hardware sourcing, potentially impacting supplier relationships and costs.
Next Steps
- Continue the comprehensive strategic review initiated by the board of directors to maximize shareholder value, considering a sale, merger, strategic business combination, or continued execution of the current strategy.
- Execute the terms of the amended Credit Agreement with Callodine Commercial Finance, LLC, including adherence to the new minimum consolidated unencumbered liquid assets covenant and monthly 13-week cash-flow reporting when liquidity is below a certain amount.
- Leverage the strategic collaboration with OneStep to expand the multi-condition digital health platform with advanced fall-risk assessment and prevention capabilities.
- Continue efforts to achieve profitability and generate positive cash flows, potentially through additional private and/or public offerings of debt or equity securities.
- File a registration statement for the shares and pre-funded warrant shares from the September 2025 offering by October 20, 2025.
Key Dates
| Date | Description |
|---|---|
| 2011-08-11 | DarioHealth Corp. incorporated in Delaware and commenced operations. |
| 2011-09-14 | LabStyle Innovation Ltd. incorporated and commenced operations in Israel. |
| 2022-06-09 | Company entered into a Credit Agreement with OrbiMed Royalty and Credit Opportunities III, LP for a $50 million senior secured credit facility and issued Orbimed Warrant. |
| 2023-05-01 | Orbimed Loan repaid in full. Company refinanced its former $25,000 credit facility with a new $30,000 credit facility (Avenue Loan Facility). |
| 2023-12 | Financial Accounting Standards Board (FASB) issued ASU 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures. |
| 2024-01-01 | Pro forma results for Twill acquisition as if it occurred on this date. |
| 2024-02-15 | Company acquired Twill, Inc. and issued Pre-Funded Warrants as part of the acquisition. |
| 2024-02 | Issuance and sale of Series C Preferred Stock, leading to adjustment of Orbimed Warrant exercise price to $80.00. |
| 2024-11 | 125,005 Pre-Funded Warrants exercised into 124,991 shares of Common Stock. FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. |
| 2024-12-16 | Company and certain purchasers executed lock-up agreements related to Series B and C Preferred Stock. |
| 2024-12-18 | Private placement transactions for Series D and D-1 preferred shares closed. |
| 2025-01-07 | Company entered into securities purchase agreements for Series D-2 and D-3 Preferred Stock. |
| 2025-01 | Company increased authorized shares under the 2020 Plan by 327,052 shares. |
| 2025-01-14 | Closing of Series D-2 and D-3 Preferred Stock offering. |
| 2025-02-12 | Expiration date for certain warrants to purchase up to 17,813 shares of Common Stock. |
| 2025-02-15 | 125,005 Pre-Funded Warrants exercised into 124,985 shares of Common Stock. |
| 2025-02-24 | Company entered into a second amendment to a consulting agreement, fixing a monthly cash retainer of $10 thousand. |
| 2025-02-25 | New non-executive director appointed to the Board, who is a member of a consulting firm providing services to the Company since 2021. |
| 2025-04-18 | Board of Directors appointed Chen Franco-Yehuda as Chief Financial Officer, Treasurer, and Secretary. |
| 2025-04-27 | Vesting date for one-third of 25,000 restricted shares granted to Ms. Franco-Yehuda. |
| 2025-04-28 | Special meeting of stockholders approved issuance of common stock related to preferred stock conversions and lock-up agreements, and reduction of exercise price for Avenue warrants. |
| 2025-04-30 | Company refinanced Avenue Loan Facility with a new $32,500 thousand credit agreement (Callodine Loan Facility) and issued warrants to lenders. Avenue Loan Facility repaid in full. |
| 2025-05-15 | Effective date for Chen Franco-Yehuda as CFO, Treasurer, and Secretary. |
| 2025-05-20 | Company filed Amended and Restated Certificates of Designation for Series A-1, B-1, C, C-1, and C-2 Preferred Stock, extending mandatory conversion period for Series C, C-1, C-2 and providing dividend terms. |
| 2025-05-23 | Start date of period when Company and holders entered into Amended and Restated Lock-Up Agreement. |
| 2025-05-28 | End date of period when Company and holders entered into Amended and Restated Lock-Up Agreement, extending restrictive period until February 21, 2026. |
| 2025-06 | Compensation Committee approved grants of restricted shares and options to employees and warrants to consultants. |
| 2025-06-01 | Expiration date for warrants to purchase up to 22,500 shares of Common Stock issued to certain consultants. |
| 2025-06-13 | Israel launched a preemptive strike targeting military and nuclear infrastructure inside Iran. |
| 2025-06-21 | United States military conducted targeted air strikes against three nuclear sites within Iran. |
| 2025-06-23 | Iran retaliated against U.S. interests in the region. |
| 2025-06-24 | Ceasefire implemented between Iran and Israel. |
| 2025-07-23 | Company's 2025 Annual Meeting of Stockholders approved the reverse stock split and amendments to the 2020 Plan. |
| 2025-08-11 | Ceasefire between Iran and Israel remains in place as of this date. |
| 2025-08-15 | Company did not meet a financial covenant under the Credit Agreement. |
| 2025-08-25 | Certificate of Amendment filed with the Secretary of State of Delaware for the reverse stock split. |
| 2025-08-28 | Effective date of the 20-for-1 reverse stock split. 125,005 Pre-Funded Warrants exercised into 124,981 shares of Common Stock. |
| 2025-09-03 | Company issued a shareholder update highlighting progress and commercial momentum. |
| 2025-09-11 | End of 10 consecutive business days where closing bid price of Common Stock was $1.00 or greater. |
| 2025-09-12 | Company received letter from Nasdaq confirming regained compliance with minimum bid price rule. |
| 2025-09-18 | Company filed Amended and Restated Certificates of Designation for Series A-1, C, C-2, D, D-1, D-2, and D-3 Preferred Stock, accelerating mandatory conversion periods. All outstanding shares of Series C, C-1, C-2 Preferred Stock converted into 982,845 shares of Common Stock. All outstanding shares of Series D, D-1, D-2, D-3 Preferred Stock converted into 1,600,043 shares of Common Stock and 776,719 pre-funded warrants. |
| 2025-09-19 | 31,766 pre-funded warrants (issued in July 2020) exercised on a cashless basis into 31,716 shares of Common Stock. |
| 2025-09-22 | Company entered into securities purchase agreements for an offering of 1,154,420 shares of Common Stock and pre-funded warrants to purchase up to 1,558,760 shares of Common Stock. |
| 2025-09-23 | Closing of the September 2025 private placement offering. |
| 2025-09-25 | Company announced initiation of a comprehensive strategic review. Company filed Amended and Restated Certificate of Designation for Series C-1 Preferred Stock, accelerating mandatory conversion period. |
| 2025-09-30 | End of the quarterly period covered by this report. No Series A-1, B-1, C, C-1, C-2, D, D-1, D-2, and D-3 Preferred Stock remains outstanding. |
| 2025-10-03 | Deadline for successful implementation of Equity Cure for Callodine covenant waiver. |
| 2025-10-06 | Company announced strategic collaboration with OneStep. |
| 2025-10-09 | Israel and Hamas entered into a ceasefire agreement. |
| 2025-10-20 | Company and holders entered into a Second Amended and Restated Lock-Up Agreement, accelerating share consideration upon a Fundamental Transaction. Company filed a registration statement for shares and pre-funded warrant shares from the September 2025 offering. |
| 2025-11-01 | Registrant had 6,768,184 shares of common stock outstanding. |
| 2025-11-05 | Company entered into an Amendment to the Credit Agreement with Lenders, resetting financial covenants and repricing warrants. |
| 2025-11-13 | Date of filing of this 10-Q report. |
| 2026-02-16 | End of Lock-Up Period for certain shares under the Second Amended and Restated Lock-Up Agreement. |
| 2026-02-21 | Extended restrictive period for certain shares under the Amended and Restated Lock-Up Agreement. |
| 2026-12-31 | End of calendar year for which the number of shares available under the 2020 Plan will be increased by 6% of outstanding common stock. |
| 2027-12-31 | End of calendar year for which the number of shares available under the 2020 Plan will be increased by 6% of outstanding common stock. Expiration date for certain warrants to purchase up to 17,813 shares of Common Stock. |
| 2028-06-01 | Expiration date for warrants to purchase up to 22,500 shares of Common Stock issued to certain consultants. |
| 2028-12-31 | End of calendar year for which the number of shares available under the 2020 Plan will be increased by 6% of outstanding common stock. |
| 2029-12-31 | End of calendar year for which the number of shares available under the 2020 Plan will be increased by 6% of outstanding common stock. |
| 2030-04 | Maturity date of the Callodine Loan Facility. |
| 2030-12-31 | End of calendar year for which the number of shares available under the 2020 Plan will be increased by 6% of outstanding common stock. |
Recommendation
holdDarioHealth Corp. presents a mixed financial picture. While the company demonstrated improved gross profit margins and reduced operating expenses, leading to a lower overall net loss, the significant decline in total revenues and a substantial increase in net loss attributable to common shareholders are concerning. The ongoing strategic review introduces considerable uncertainty but also potential for value creation through a sale or merger. The recent capital raise and debt covenant amendment provide short-term liquidity and stability, but the company's long-term profitability remains dependent on successful commercialization and further funding. Given the revenue contraction, the volatility of the stock, and the uncertainty surrounding the strategic review, a 'hold' recommendation is appropriate. Investors should monitor the outcome of the strategic review and future revenue trends before making further investment decisions.
Keywords
Digital Therapeutics, Chronic Condition Management, DarioHealth, DRIO, SEC Filing, 10-Q, Financial Results, Digital Health, Telehealth, Behavioral Health, Diabetes Management, Hypertension, Weight Management, Musculoskeletal Pain, Strategic Review, Reverse Stock Split, Nasdaq Compliance, Private Placement, Debt Covenant, Q3 2025 Earnings
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.